[{"id":"d63d90c7-ce00-45f0-be6c-08cf85a450c7","acronym":"MANTRA-4","url":"https://clinicaltrials.gov/study/NCT06090318","created_at":"2023-10-19T17:12:57.672Z","updated_at":"2024-07-02T16:35:32.632Z","phase":"Phase 1b/2","brief_title":"Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss","source_id_and_acronym":"NCT06090318 - MANTRA-4","lead_sponsor":"Rain Oncology Inc","biomarkers":" TP53 • CDKN2A","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • milademetan (RAIN-32)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2023-10-19"},{"id":"613e409a-9659-4396-bba3-22b9a39d0fcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877382","created_at":"2021-01-18T08:26:57.296Z","updated_at":"2024-07-02T16:36:37.709Z","phase":"Phase 1","brief_title":"A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT01877382","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" TP53 • MDM2 • GDF15","pipe":" | ","alterations":" TP53 mutation • MDM2 amplification • MDM2 overexpression","tags":["TP53 • MDM2 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MDM2 amplification • MDM2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milademetan (RAIN-32)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-08"}]